NY State Senate Bill S2816B

Archive: Last Bill Status Via A587 - Signed by Governor

Introduced
In Committee
On Floor Calendar
- Passed Senate
- Passed Assembly
Delivered to Governor
Signed by Governor

Your Voice

Please enter your contact information

First Name *

Last Name *

Email Address *

A valid email address is required.

Home address search or enter your address manually *

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Leave this field blank

Actions

view actions (25)

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Oct 02, 2018	signed chap.307
Sep 20, 2018	delivered to governor
Jun 04, 2018	returned to assembly passed senate 3rd reading cal.1230 substituted for s2816b
Jun 04, 2018	substituted by a587c
May 22, 2018	advanced to third reading
May 16, 2018	2nd report cal.
May 15, 2018	1st report cal.1230
Mar 22, 2018	print number 2816b
Mar 22, 2018	amend and recommit to finance
Feb 27, 2018	reported and committed to finance
Jan 12, 2018	print number 2816a
Jan 12, 2018	amend and recommit to health
Jan 03, 2018	referred to health returned to senate died in assembly
Jun 14, 2017	referred to health delivered to assembly passed senate
Mar 20, 2017	advanced to third reading
Mar 15, 2017	2nd report cal.
Mar 13, 2017	1st report cal.411
Jan 17, 2017	referred to health

Votes

Bill Amendments

Original

B (Active)

Original

B (Active)

Co-Sponsors

S2816 - Details

See Assembly Version of this Bill:: A587
Law Section:: Public Health Law
Laws Affected:: Amd §§2500-a & 207, Pub Health L

S2816 - Summary

Requires urine polymerase chain reaction testing for cytomegalovirus of newborns with hearing impairments; and directs the department of health to establish an education program for women who may become pregnant, expectant parents and parents of infants relating to various aspects of cytomegalovirus.

S2816 - Sponsor Memo

 BILL NUMBER:  S2816

 TITLE OF BILL :  An act to amend the public health law, in relation
to the testing of certain newborns for cytomegalovirus and public
education thereon

 PURPOSE :

To provide testing for CMV if a newborn infant is identified as or
suspected of having a hearing impairment as well as to promote public
awareness and education of CMV.

 SUMMARY OF PROVISIONS :

Section 1 amends section 2500-a of the Public Health Law to require
that any newborn identified as or suspected of having a hearing
impairment be tested for cytomegalovirus unless a parent of the
newborn infant objects.

Section 2 adds section 2500-1 to the Public Health Law entitled
Cytomegalovirus Public Education. Subdivision (1) requires the
Department of Health to develop and publish informational materials
for women who may become pregnant, expectant parents and parents of
infants regards cytomegalovirus. Subdivision (2) directs the DOH to
publish the information required under section (1) to its internet
website and distribute information regarding birth defects, treatment

and resources to all hospitals performing cytomegalovirus testing
pursuant to public health law section 2500-a. Subdivision (3) allows
the Department to establish rules to implement the purpose of this
section.

Section 3 provides an immediate effective date.

 JUSTIFICATION :

Cytomegalovirus (CMV) is the most common congenital viral infection
and the leading non-genetic cause of deafness in children. Although
most CMV infections are silent, meaning the majority of people who are
infected with CMV have no signs or symptoms and while there are no
harmful side effects, its effects can be devastating to a fetus.
Every year, 20,000 to 40,000 infants are born with CMV and roughly 400
children die from CMV annually. Congenital CMV infection is largely
undetected because the majority of infants are asymptomatic at birth.
At least 20 percent (up to 8,000) infants have or develop permanent
disabilities, such as hearing loss, microcephaly, intellectual
deficits and vision abnormalities. While such cases are fortunately
relatively rare, CMV is four times more prevalent than Zika in the
U.S. and the state has spent millions to fight Zika.

CMV is transmitted by contact with saliva and urine-often from diaper
wearing children to adults. Pregnant women often get CMV from their
toddlers, especially toddlers in day care, as nearly one in three
children are infected by age five. Significantly, the American College
of Obstetricians and Gynecologists used to encourage counseling for
pregnant women on how to avoid CMV but last year, the college reversed
course claiming that patient instruction remains unproven as a method
to reduce the risk of congenital CMV infection.  However, it is hard
for mothers to protect themselves from a virus carried by the children
they care for, especially if they are unaware of the virus
itself--less than one in five pregnant women are aware of
cytomegalovirus. Few women are warned about this infection and
according to a federal survey, less than half of
obstetrician-gynecologists tell pregnant patients how to avoid CMV.
Researchers say that pregnant women do not worry about CMV only
because they do not know about it, which is why it is crucial for

women who are pregnant or may become pregnant to be aware of available
preventative measures, such as not sharing food with toddlers.

This legislation aims to raise public awareness and reduce the
transmission of CMV to a woman from a toddler by educating women about
the virus itself and simple preventative measures, such as washing
ones hands after changing infants and toddlers diapers. This
legislation also aims to promote earlier detection of CMV in infants
who are identified or suspected of having a hearing impairment. A test
for CMV can be done immediately upon receiving the results from the
newborn-infant hearing screening, which typically occurs at a facility
before a newborn is discharged. Significantly, infants who receive a
timely diagnosis can be given hearing aids or access to
early-intervention programs to have the best chance of learning to
talk. A study published in The New England Journal of Medicine last
year found that infants with CMV symptoms at birth who took an
antiviral drug for six months had moderately better hearing at 2 years
compared with newborns who took it for six weeks (see
http://www.nejm.org/doifful1/10.1056/NEJMoa1404599#t=article). Recent
evidence suggests that routine screening of newborns could allow
infected infants to receive consistent monitoring and treatment if
necessary, ultimately increasing his/her chance of optimize d
developmental care. This act is aimed at making parents aware of what
their options are if their child is determined to have CMV.

In 2013, the Utah legislature passed the Cytomegalovirus Public Health
Initiative, which requires CMV screening of newborns who did not pass
hearing tests. Connecticut, Hawaii, Illinois, Texas and Tennessee
subsequently followed suit. Idaho, Michigan, Minnesota, Pennsylvania,
South Carolina and Wyoming are currently working through similar
legislation.

 LEGISLATIVE HISTORY :

New bill.

 FISCAL IMPLICATIONS :

None.

 EFFECTIVE DATE :
This act shall take effect immediately.

S2816 - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  2816

                       2017-2018 Regular Sessions

                            I N  S E N A T E

                            January 17, 2017
                               ___________

Introduced  by  Sen.  HANNON -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation  to  the  testing  of
  certain newborns for cytomegalovirus and public education thereon

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Subdivision (a) of section 2500-a of the public health law,
as amended by chapter 184 of the laws of 2013, is  amended  to  read  as
follows:
  (a) It shall be the duty of the administrative officer or other person
in  charge  of  each institution caring for infants twenty-eight days or
less of age and the person required in pursuance of  the  provisions  of
section  forty-one  hundred thirty of this chapter to register the birth
of a child, to cause to have administered to every such infant or  child
in  its  or  his care a test for phenylketonuria, homozygous sickle cell
disease, hypothyroidism, branched-chain ketonuria,  galactosemia,  homo-
cystinuria,  critical  congenital  heart  defects through pulse oximetry
screening, AND WITH REGARD TO ANY NEWBORN INFANT WHO IS  IDENTIFIED  AS,
OR  SUSPECTED OF, HAVING A HEARING IMPAIRMENT AS A RESULT OF A SCREENING
CONDUCTED PURSUANT TO SECTION TWENTY-FIVE HUNDRED-G OF THIS TITLE, CAUSE
TO BE ADMINISTERED TO SUCH INFANT A TEST FOR CYTOMEGALOVIRUS, UNLESS THE
PARENT OF THE INFANT OBJECTS THERETO, and such other diseases and condi-
tions as may from time to time be  designated  by  the  commissioner  in
accordance  with  rules  or  regulations prescribed by the commissioner.
Testing, the recording of the results of such tests, tracking, follow-up
reviews and educational activities shall be performed at such times  and
in such manner as may be prescribed by the commissioner. The commission-
er shall promulgate regulations setting forth the manner in which infor-
mation describing the purposes of the requirements of this section shall
be disseminated to parents or a guardian of the infant tested.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD05326-02-7

S. 2816                             2

  §  2.  The public health law is amended by adding a new section 2500-1
to read as follows:
  §  2500-1.  CYTOMEGALOVIRUS  PUBLIC EDUCATION. 1. THE DEPARTMENT SHALL
DEVELOP AND PUBLISH INFORMATIONAL MATERIALS FOR  WOMEN  WHO  MAY  BECOME
PREGNANT, EXPECTANT PARENTS AND PARENTS OF INFANTS REGARDING:
  (A) THE INCIDENCE OF CYTOMEGALOVIRUS;
  (B)  THE  TRANSMISSION  AND RISKS OF CYTOMEGALOVIRUS TO PREGNANT WOMEN
AND WOMEN WHO MAY BECOME PREGNANT;
  (C) BIRTH DEFECTS CAUSED BY CONGENITAL CYTOMEGALOVIRUS;
  (D) METHODS OF DIAGNOSING CONGENITAL CYTOMEGALOVIRUS;
  (E) THE AVAILABLE PREVENTIVE MEASURES TO AVOID THE INFECTION OF  WOMEN
WHO ARE PREGNANT OR MAY BECOME PREGNANT; AND
  (F) AVAILABLE METHODS OF TREATING CYTOMEGALOVIRUS AND RESOURCES AVAIL-
ABLE FOR FAMILIES OF CHILDREN BORN WITH CYTOMEGALOVIRUS.
  2.  THE  DEPARTMENT SHALL PUBLISH THE INFORMATION REQUIRED PURSUANT TO
SUBDIVISION ONE OF THIS SECTION ON ITS INTERNET WEBSITE, AND  DISTRIBUTE
INFORMATION  REGARDING  BIRTH  DEFECTS,  TREATMENT  AND RESOURCES TO ALL
HOSPITALS PERFORMING CYTOMEGALOVIRUS TESTING PURSUANT TO  SECTION  TWEN-
TY-FIVE HUNDRED-A OF THIS TITLE.
  3.  THE  DEPARTMENT  MAY PROMULGATE RULES TO IMPLEMENT THE PURPOSES OF
THIS SECTION.
  § 3. This act shall take effect immediately; except that  section  one
of  this act shall take effect on the one hundred twentieth day after it
shall have become a law; provided, however, that effective  immediately,
the  addition,  amendment and/or repeal of any rule or regulation neces-
sary for the implementation of section one of this act on its  effective
date  are  authorized and directed to be made and completed on or before
such effective date.

Co-Sponsors

S2816A - Details

See Assembly Version of this Bill:: A587
Law Section:: Public Health Law
Laws Affected:: Amd §§2500-a & 207, Pub Health L

S2816A - Summary

S2816A - Sponsor Memo

 
BILL NUMBER: S2816A

SPONSOR: HANNON
 
TITLE OF BILL:  An act to amend the public health law, in relation to
the testing of certain newborns for cytomegalovirus and public education
thereon

 
PURPOSE:

To provide testing for CMV if a newborn infant is identified as or
suspected of having a hearing impairment as well as to promote public
awareness and education of CMV.

 
SUMMARY OF PROVISIONS:

Section 1 amends section 2500-a of the Public Health Law to require that
any newborn identified as or suspected of having a hearing impairment be
tested for cytomegalovirus unless a parent of the newborn infant
objects.

Section 2 adds section 2500-1 to the Public Health Law entitled Cytome-

galovirus Public Education. Subdivision (1) requires the Department of
Health to develop and publish informational materials for women who may
become pregnant, expectant parents and parents of infants regards cyto-
megalovirus. Subdivision (2) directs the DOH to publish the information
required under section (1) to its internet website and distribute infor-
mation regarding birth defects, treatment and resources to all hospitals
performing cytomegalovirus testing pursuant to public health law section
2500-a. Subdivision (3) allows the Department to establish rules to
implement the purpose of this section.

Section 3 provides an immediate effective date.

 
JUSTIFICATION:

Cytomegalovirus (CMV) is the most common congenital viral infection and
the leading non-genetic cause of deafness in children. Although most CMV
infections are silent, meaning the majority of people who are infected
with CMV have no signs or symptoms and while there are no harmful side
effects, its effects can be devastating to a fetus.  Every year, 20,000
to 40,000 infants are born with CMV and roughly 400 children die from
CMV annually. Congenital CMV infection is largely undetected because the
majority of infants are asymptomatic at birth. At least 20 percent (up
to 8,000) infants have or develop permanent disabilities, such as hear-
ing loss, microcephaly, intellectual deficits and vision abnormalities.
While such cases are fortunately relatively rare, CMV is four times more
prevalent than Zika in the U.S. and the state has spent millions to
fight Zika.

CMV is transmitted by contact with saliva and urine-often from diaper
wearing children to adults. Pregnant women often get CMV from their
toddlers, especially toddlers in day care, as nearly one in three chil-
dren are infected by age five. Significantly, the American College of
Obstetricians and Gynecologists used to encourage counseling for preg-
nant women on how to avoid CMV but last year, the college reversed
course claiming that patient instruction remains unproven as a method to
reduce the risk of congenital CMV infection.  However, it is hard for
mothers to protect themselves from a virus carried by the children they
care for, especially if they are unaware of the virus itself--less than
one in five pregnant women are aware of cytomegalovirus. Few women are
warned about this infection and according to a federal survey, less than
half of obstetrician-gynecologists tell pregnant patients how to avoid
CMV.  Researchers say that pregnant women do not worry about CMV only
because they do not know about it, which is why it is crucial for women
who are pregnant or may become pregnant to be aware of available preven-
tative measures, such as not sharing food with toddlers.

This legislation aims to raise public awareness and reduce the trans-
mission of CMV to a woman from a toddler by educating women about the
virus itself and simple preventative measures, such as washing ones
hands after changing infants and toddlers diapers. This legislation also
aims to promote earlier detection of CMV in infants who are identified
or suspected of having a hearing impairment. A test for CMV can be done
immediately upon receiving the results from the newborn-infant hearing
screening, which typically occurs at a facility before a newborn is
discharged. Significantly, infants who receive a timely diagnosis can be
given hearing aids or access to early-intervention programs to have the
best chance of learning to talk. A study published in The New England
Journal of Medicine last year found that infants with CMV symptoms at
birth who took an antiviral drug for six months had moderately better
hearing at 2 years compared with newborns who took it for six weeks (see
http://www.nejm.org/doilii11/10.1056/NEIMoa140459544-article). Recent
evidence suggests that routine screening of newborns could allow
infected infants to receive consistent monitoring and treatment if
necessary, ultimately increasing his/her chance of optimize d develop-
mental care. This act is aimed at making parents aware of what their
options are if their child is determined to have CMV.

In 2013, the Utah legislature passed the Cytomegalovirus Public Health
Initiative, which requires CMV screening of newborns who did not pass
hearing tests. Connecticut, Hawaii, Illinois, Texas and Tennessee subse-
quently followed suit. Idaho, Michigan, Minnesota, Pennsylvania, South
Carolina and Wyoming are currently working through similar legislation.

 
LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect immediately.

S2816A - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 2816--A

                       2017-2018 Regular Sessions

                            I N  S E N A T E

                            January 17, 2017
                               ___________

Introduced  by  Sens.  HANNON,  AVELLA, SAVINO -- read twice and ordered
  printed, and when printed to be committed to the Committee  on  Health
  --  recommitted  to  the Committee on Health in accordance with Senate
  Rule  6,  sec.  8  --  committee  discharged,  bill  amended,  ordered
  reprinted as amended and recommitted to said committee

AN  ACT  to  amend  the public health law, in relation to the testing of
  certain newborns for cytomegalovirus and public education thereon

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Subdivision (a) of section 2500-a of the public health law,
as  amended  by  chapter  184 of the laws of 2013, is amended to read as
follows:
  (a) It shall be the duty of the administrative officer or other person
in charge of each institution caring for infants  twenty-eight  days  or
less  of  age  and the person required in pursuance of the provisions of
section forty-one hundred thirty of this chapter to register  the  birth
of  a child, to cause to have administered to every such infant or child
in its or his care a test for phenylketonuria,  homozygous  sickle  cell
disease,  hypothyroidism,  branched-chain ketonuria, galactosemia, homo-
cystinuria, critical congenital heart  defects  through  pulse  oximetry
screening,  AND  WITH REGARD TO ANY NEWBORN INFANT WHO IS IDENTIFIED AS,
OR SUSPECTED OF, HAVING A HEARING IMPAIRMENT AS A RESULT OF A  SCREENING
CONDUCTED PURSUANT TO SECTION TWENTY-FIVE HUNDRED-G OF THIS TITLE, CAUSE
TO  BE  ADMINISTERED  TO  SUCH  INFANT A URINE POLYMERASE CHAIN REACTION
(PCR) TEST FOR CYTOMEGALOVIRUS, UNLESS THE PARENT OF THE INFANT  OBJECTS
THERETO, and such other diseases and conditions as may from time to time
be  designated  by  the  commissioner  in accordance with rules or regu-
lations prescribed by the commissioner. Testing, the  recording  of  the
results  of  such  tests,  tracking,  follow-up  reviews and educational
activities shall be performed at such times and in such manner as may be
prescribed by the commissioner. The commissioner shall promulgate  regu-

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD05326-03-7

S. 2816--A                          2

lations  setting  forth  the  manner in which information describing the
purposes of the requirements of this section shall  be  disseminated  to
parents or a guardian of the infant tested.
  §  2.  The public health law is amended by adding a new section 2500-1
to read as follows:
  § 2500-1. CYTOMEGALOVIRUS PUBLIC EDUCATION. 1.  THE  DEPARTMENT  SHALL
DEVELOP  AND  PUBLISH  INFORMATIONAL  MATERIALS FOR WOMEN WHO MAY BECOME
PREGNANT, EXPECTANT PARENTS AND PARENTS OF INFANTS REGARDING:
  (A) THE INCIDENCE OF CYTOMEGALOVIRUS;
  (B) THE TRANSMISSION AND RISKS OF CYTOMEGALOVIRUS  TO  PREGNANT  WOMEN
AND WOMEN WHO MAY BECOME PREGNANT;
  (C) BIRTH DEFECTS CAUSED BY CONGENITAL CYTOMEGALOVIRUS;
  (D) METHODS OF DIAGNOSING CONGENITAL CYTOMEGALOVIRUS;
  (E)  THE AVAILABLE PREVENTIVE MEASURES TO AVOID THE INFECTION OF WOMEN
WHO ARE PREGNANT OR MAY BECOME PREGNANT; AND
  (F) AVAILABLE METHODS OF TREATING CYTOMEGALOVIRUS AND RESOURCES AVAIL-
ABLE FOR FAMILIES OF CHILDREN BORN WITH CYTOMEGALOVIRUS.
  2. THE DEPARTMENT SHALL PUBLISH THE INFORMATION REQUIRED  PURSUANT  TO
SUBDIVISION  ONE OF THIS SECTION ON ITS INTERNET WEBSITE, AND DISTRIBUTE
INFORMATION REGARDING BIRTH DEFECTS,  TREATMENT  AND  RESOURCES  TO  ALL
HOSPITALS  PERFORMING  CYTOMEGALOVIRUS TESTING PURSUANT TO SECTION TWEN-
TY-FIVE HUNDRED-A OF THIS TITLE.
  3. THE DEPARTMENT MAY PROMULGATE RULES TO IMPLEMENT  THE  PURPOSES  OF
THIS SECTION.
  §  3.  This act shall take effect immediately; except that section one
of this act shall take effect on the one hundred twentieth day after  it
shall  have become a law; provided, however, that effective immediately,
the addition, amendment and/or repeal of any rule or  regulation  neces-
sary  for the implementation of section one of this act on its effective
date are authorized and directed to be made and completed on  or  before
such effective date.

Co-Sponsors

S2816B (ACTIVE) - Details

See Assembly Version of this Bill:: A587
Law Section:: Public Health Law
Laws Affected:: Amd §§2500-a & 207, Pub Health L

S2816B (ACTIVE) - Summary

S2816B (ACTIVE) - Sponsor Memo

 
BILL NUMBER: S2816B

SPONSOR: HANNON
 
TITLE OF BILL:  An act to amend the public health law, in relation to
the testing of certain newborns for cytomegalovirus and public education
thereon

 
PURPOSE:

To provide testing for CMV if a newborn infant is identified as or
suspected of having a hearing impairment as well as to promote public
awareness and education of CMV.

 
SUMMARY OF PROVISIONS:

Section 1 amends section 2500-a of the Public Health Law to require that
any newborn identified as or suspected of having a hearing impairment be
tested for cytomegalovirus unless a parent of the newborn infant
objects.

Section 2 adds section 2500-1 to the Public Health Law entitled Cytome-

galovirus Public Education. Subdivision (1) requires the Department of
Health to develop and publish informational materials for women who may
become pregnant, expectant parents and parents of infants regards cyto-
megalovirus. Subdivision (2) directs the DOH to publish the information
required under section (1) to its internet website and distribute infor-
mation regarding birth defects, treatment and resources to all hospitals
performing cytomegalovirus testing pursuant to public health law section
2500-a. Subdivision (3) allows the Department to establish rules to
implement the purpose of this section.

Section 3 provides an immediate effective date.

 
JUSTIFICATION:

Cytomegalovirus (CMV) is the most common congenital viral infection and
the leading non-genetic cause of deafness in children. Although most CMV
infections are silent, meaning the majority of people who are infected
with CMV have no signs or symptoms and while there are no harmful side
effects, its effects can be devastating to a fetus.  Every year, 20,000
to 40,000 infants are born with CMV and roughly 400 children die from
CMV annually. Congenital CMV infection is largely undetected because the
majority of infants are asymptomatic at birth. At least 20 percent (up
to 8,000) infants have or develop permanent disabilities, such as hear-
ing loss, microcephaly, intellectual deficits and vision abnormalities.
While such cases are fortunately relatively rare, CMV is four times more
prevalent than Zika in the U.S. and the state has spent millions to
fight Zika.

CMV is transmitted by contact with saliva and urine-often from diaper
wearing children to adults. Pregnant women often get CMV from their
toddlers, especially toddlers in day care, as nearly one in three chil-
dren are infected by age five. Significantly, the American College of
Obstetricians and Gynecologists used to encourage counseling for preg-
nant women on how to avoid CMV but last year, the college reversed
course claiming that patient instruction remains unproven as a method to
reduce the risk of congenital CMV infection. However, it is hard for
mothers to protect themselves from a virus carried by the children they
care for, especially if they are unaware of the virus itself--less than
one in five pregnant women are aware of cytomegalovirus. Few women are
warned about this infection and according to a federal survey, less than
half of obstetrician-gynecologists tell pregnant patients how to avoid
CMV.  Researchers say that pregnant women do not worry about CMV only
because they do not know about it, which is why it is crucial for women
who are pregnant or may become pregnant to be aware of available preven-
tative measures, such as not sharing food with toddlers.

This legislation aims to raise public awareness and reduce the trans-
mission of CMV to a woman from a toddler by educating women about the
virus itself and simple preventative measures, such as washing ones
hands after changing infants and toddlers diapers. This legislation also
aims to promote earlier detection of CMV in infants who are identified
or suspected of having a hearing impairment. A test for CMV can be done
immediately upon receiving the results from the newborn-infant hearing
screening, which typically occurs at a facility before a newborn is
discharged. Significantly, infants who receive a timely diagnosis can be
given hearing aids or access to early-intervention programs to have the
best chance of learning to talk. A study published in The New England
Journal of Medicine last year found that infants with CMV symptoms at
birth who took an antiviral drug for six months had moderately better
hearing at 2 years compared with newborns who took it for six weeks (see
http://www.nejm.org/doi/ful1/10.1056/NEJMoa14045994-article). Recent
evidence suggests that routine screening of newborns could allow
infected infants to receive consistent monitoring and treatment if
necessary, ultimately increasing his/her chance of optimized develop-
mental care. This act is aimed at making parents aware of what their
options are if their child is determined to have CMV.

In 2013, the Utah legislature passed the Cytomegalovirus Public Health
Initiative, which requires CMV screening of newborns who did not pass
hearing tests. Connecticut, Hawaii, Illinois, Texas and Tennessee subse-
quently followed suit. Idaho, Michigan, Minnesota, Pennsylvania, South
Carolina and Wyoming are currently working through similar legislation.

 
LEGISLATIVE HISTORY:

New bill.

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect immediately.

S2816B (ACTIVE) - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 2816--B

                       2017-2018 Regular Sessions

                            I N  S E N A T E

                            January 17, 2017
                               ___________

Introduced  by  Sens.  HANNON, AVELLA, LARKIN, MARCHIONE, SAVINO -- read
  twice and ordered printed, and when printed to  be  committed  to  the
  Committee  on  Health  --  recommitted  to  the Committee on Health in
  accordance with Senate Rule 6, sec. 8 --  committee  discharged,  bill
  amended,  ordered reprinted as amended and recommitted to said commit-
  tee -- reported favorably from said committee  and  committed  to  the
  Committee  on  Finance  -- committee discharged, bill amended, ordered
  reprinted as amended and recommitted to said committee

AN ACT to amend the public health law, in relation  to  the  testing  of
  certain newborns for cytomegalovirus and public education thereon

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Subdivision (a) of section 2500-a of the public health law,
as amended by chapter 184 of the laws of 2013, is  amended  to  read  as
follows:
  (a)  1.  It  shall  be the duty of the administrative officer or other
person in charge of each institution  caring  for  infants  twenty-eight
days  or  less  of  age  and  the  person  required  in pursuance of the
provisions of section forty-one hundred thirty of this chapter to regis-
ter the birth of a child, to cause to have administered  to  every  such
infant or child in its or his care a test for:
  I. phenylketonuria,
  II. homozygous sickle cell disease,
  III. hypothyroidism,
  IV. branched-chain ketonuria,
  V. galactosemia,
  VI. homocystinuria,
  VII.  critical congenital heart defects through pulse oximetry screen-
ing, [and]
  VIII. WITH REGARD TO ANY NEWBORN  INFANT  WHO  IS  IDENTIFIED  AS,  OR
SUSPECTED  OF,  HAVING  A  HEARING IMPAIRMENT AS A RESULT OF A SCREENING

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD05326-04-8

S. 2816--B                          2

CONDUCTED PURSUANT TO SECTION TWENTY-FIVE HUNDRED-G OF THIS TITLE, CAUSE
TO BE ADMINISTERED TO SUCH INFANT  A  URINE  POLYMERASE  CHAIN  REACTION
(PCR)  TEST FOR CYTOMEGALOVIRUS, UNLESS THE PARENT OF THE INFANT OBJECTS
THERETO;  PROVIDED THAT IF THE COMMISSIONER DETERMINES THAT ANOTHER TEST
FOR CYTOMEGALOVIRUS IS DIAGNOSTICALLY EQUIVALENT TO OR BETTER  THAN  THE
URINE  POLYMERASE  CHAIN  REACTION  TEST, THE COMMISSIONER MAY, BY REGU-
LATION UNDER THIS SECTION, ALLOW OR REQUIRE THE USE OF THAT OTHER  TEST,
and
  IX.  such  other  diseases  and conditions as may from time to time be
designated by the commissioner in accordance with rules  or  regulations
prescribed by the commissioner.
  2.  Testing,  the  recording  of  the results of such tests, tracking,
follow-up reviews and educational activities shall be performed at  such
times  and  in such manner as may be prescribed by the commissioner. The
commissioner shall promulgate regulations setting forth  the  manner  in
which  information  describing  the purposes of the requirements of this
section shall be disseminated to parents or a  guardian  of  the  infant
tested.
  §  2. Subdivision 1 of section 207 of the public health law is amended
by adding a new paragraph (o) to read as follows:
  (O) FOR WOMEN WHO MAY BECOME PREGNANT, EXPECTANT PARENTS  AND  PARENTS
OF INFANTS, INFORMATION REGARDING:
  (I) THE INCIDENCE OF CYTOMEGALOVIRUS;
  (II)  THE  TRANSMISSION AND RISKS OF CYTOMEGALOVIRUS TO PREGNANT WOMEN
AND WOMEN WHO MAY BECOME PREGNANT;
  (III) BIRTH DEFECTS CAUSED BY CONGENITAL CYTOMEGALOVIRUS;
  (IV) METHODS OF DIAGNOSING CONGENITAL CYTOMEGALOVIRUS;
  (V) THE AVAILABLE PREVENTIVE MEASURES TO AVOID THE INFECTION OF  WOMEN
WHO ARE PREGNANT OR MAY BECOME PREGNANT; AND
  (VI)  AVAILABLE  METHODS  OF  TREATING  CYTOMEGALOVIRUS  AND RESOURCES
AVAILABLE FOR FAMILIES OF CHILDREN BORN WITH CYTOMEGALOVIRUS.
  § 3. This act shall take effect immediately; provided,  however,  that
section  one  of this act shall take effect on the one hundred twentieth
day after it shall have become a law. Effective immediately,  the  addi-
tion,  amendment  and/or  repeal of any rule or regulation necessary for
the implementation of section one of this act on its effective date  are
authorized  and  directed  to  be  made  and completed on or before such
effective date.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

The New York State Senate

senate Bill S2816B

Sponsored By

Archive: Last Bill Status Via A587 - Signed by Governor

Your Voice

Actions

Votes

Jun 4, 2018 - floor Vote

Floor Vote: Jun 4, 2018

May 15, 2018 - Finance committee Vote

Finance Committee Vote: May 15, 2018

Feb 27, 2018 - Health committee Vote

Committee Vote: Feb 27, 2018

Jun 14, 2017 - floor Vote

Floor Vote: Jun 14, 2017

Mar 14, 2017 - Health committee Vote

Committee Vote: Mar 14, 2017

Bill Amendments

Co-Sponsors

S2816 - Details

S2816 - Summary

S2816 - Sponsor Memo

S2816 - Bill Text download pdf

Co-Sponsors

S2816A - Details

S2816A - Summary

S2816A - Sponsor Memo

S2816A - Bill Text download pdf

Co-Sponsors

S2816B (ACTIVE) - Details

S2816B (ACTIVE) - Summary

S2816B (ACTIVE) - Sponsor Memo

S2816B (ACTIVE) - Bill Text download pdf

Comments

senate Bill S2816B

Share this bill

Sponsored By

Archive: Last Bill Status Via A587 - Signed by Governor

Your Voice

Actions

Votes

Jun 4, 2018 - floor Vote

Floor Vote: Jun 4, 2018

May 15, 2018 - Finance committee Vote

Finance Committee Vote: May 15, 2018

Feb 27, 2018 - Health committee Vote

Committee Vote: Feb 27, 2018

Jun 14, 2017 - floor Vote

Floor Vote: Jun 14, 2017

Mar 14, 2017 - Health committee Vote

Committee Vote: Mar 14, 2017

Bill Amendments

Co-Sponsors

S2816 - Details

S2816 - Summary

S2816 - Sponsor Memo

S2816 - Bill Text download pdf

Co-Sponsors

S2816A - Details

S2816A - Summary

S2816A - Sponsor Memo

S2816A - Bill Text download pdf

Co-Sponsors

S2816B (ACTIVE) - Details

S2816B (ACTIVE) - Summary

S2816B (ACTIVE) - Sponsor Memo

S2816B (ACTIVE) - Bill Text download pdf

Comments